<DOC>
	<DOCNO>NCT01602887</DOCNO>
	<brief_summary>This BA study compare bioavailability two new capsule formulation one solution formulation isethionate capsule use phase 1 2 trial healthy volunteer .</brief_summary>
	<brief_title>Relative Bioavailability Study</brief_title>
	<detailed_description />
	<mesh_term>Palbociclib</mesh_term>
	<criteria>Healthy male and/or female subject . Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12 lead ECG clinical laboratory test . Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . An informed consent document sign date subject legal representative , applicable . Subjects willing able comply schedule visit , treatment plan , laboratory test , study procedure . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Any condition possibly affect drug absorption ( eg , gastrectomy ) . A positive urine drug screen . History regular alcohol consumption exceed 7 drinks/week female 14 drinks/week male ( 1 drink = 5 ounce ( 150 mL ) wine 12 ounce ( 360 mL ) beer 1.5 ounce ( 45 mL ) hard liquor within 6 month Screening . Treatment investigational drug within 30 day ( determined local requirement , whichever long ) 5 half life precede first dose study medication . Screening supine blood pressure great equal to140 mm Hg ( systolic ) great equal 90 mm Hg ( diastolic ) , single measurement per local SOP . 12 lead ECG demonstrate QTc &gt; 450 msec QRS interval &gt; 120 msec Screening . If QTc exceed 450 msec , QRS exceed 120 msec , ECG repeat two time average three QTc QRS value use determine subject 's eligibility . Pregnant nursing female ; female childbearing potential , include tubal ligation . To consider enrollment , woman 45 55 year age postmenopausal ( define amenorrheic least 2 year ) must confirmatory FSH test result Screening . Use prescription nonprescription drug dietary supplement within 7 day 5 half life ( whichever longer ) prior first dose study medication . Herbal supplement hormone replacement therapy must discontinue 28 day prior first dose study medication . As exception , acetaminophen/paracetamol may use dos less equal to1 g/day . Limited use non prescription medication believe affect subject safety overall result study may permit casebycase basis follow approval sponsor . Blood donation approximately 1 pint ( 500 mL ) within 56 day prior dose . Unwilling unable comply Lifestyle Guidelines describe protocol . Subjects investigational site staff member relatives site staff member subject Pfizer employee directly involve conduct trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>BA/BE</keyword>
	<keyword>PK</keyword>
	<keyword>PD-0332991</keyword>
	<keyword>PF-05089326</keyword>
	<keyword>Breast Cancer</keyword>
</DOC>